You are now leaving the ViiV Healthcare website and being re-directed to an external website
Explore ViiV Healthcare
Learn about our latest research
Read the report, available now in English and Spanish
As the only company solely focused on HIV, we go beyond developing new medicines. We take a holistic approach to HIV by developing and supporting sustainable community programs — with and for the HIV community.
ViiV Healthcare has a long-standing commitment to activities that deliver education, treatment and prevention and access to care through on-the-ground programs.
The voice of the HIV community informs everything we do to improve the lives and health outcomes of all people living with HIV.
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV
ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021
Read all news
We must stand together to reduce disparities in communities disproportionately impacted by HIV, with the goal of leaving no person living with HIV behind.
Read how to report a side effect.
Website images are not intended to imply that the models pictured have HIV.
©2018 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare US, Five Moore Drive, Research Triangle Park, North Carolina USA, 27709-3398.
Connect with us